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The small market for veterinary medicines in Finland
poses challenges for the authorities and the veterinary
medicines industry. The industry operates on business
economic principles. On the one hand, there is – under-
standable – reluctance to offer for sale unprofitable
products. On the other hand, necessary medicines
should be available to veterinarians. Pet owners are pre-
pared to pay more and more for the treatment of their
pets, and demand up-to-date methods of treatment. It
would benefit everyone to have on the market veteri-
nary medicinal products with marketing authorisations
so that their quality, safety and efficacy are appropriate-
ly assessed, and they are sold with appropriate instruc-
tions for use on the packaging. At present, the problems
in availability of veterinary medicines are being patched
up with the special license system.
The control of veterinary medicine has many special
characteristics: There are many animal species, from
dogs and cows to fish and chickens; the medicine may
end up in the environment (e.g. medicine for fish) and
cause harm to the environment. The consumer may be
exposed to residues of medicine which have made their
way into food, and the person administering medication
may react adversely to the substance. Many veterinary
medicines are immunological products, i.e. vaccines.
There are safety risks related to vaccines, as well: A live
vaccine may contain a virus that does not belong there.
Such a virus would not pose a problem, if it were al-
ready present in the country, but a virus of foreign ori-
gin could cause serious outbreaks of animal diseases in
Finland. In these cases, for instance, the National
Agency for Medicines utilises a wide external network
of experts.
The human safety is one of the important issues re-
ceiving special attention in the control of veterinary
medicines. The medication of food-producing animals
can result in residues of the medicine present in food-
stuffs made of the animal in question, and that could be
harmful for the consumer. For this reason, special atten-
tion has traditionally been paid to setting the withdraw-
al periods for veterinary medicines in Finland and the
other Nordic countries. In Finland, the withdrawal peri-
ods for old medicines were reviewed in 1999, while
their marketing authorisations were renewed. It would
seem that the EU is gradually adopting the method of
assessing the withdrawal periods of new medicines prac-
tised by the Nordic countries.
The operator safety is another very important issue
when assessing the safety of veterinary medicines. The
operator may, for example, be exposed to external para-
site medication or preparations applied by nebulization
(spraying), containing sensitising agents. Correct in-
structions for dosage and use protect the operator; it is
therefore important to read the instructions in the pack-
age insert before administering the medicine.
The third important issue pertaining to the safety of
humans is the drug resistance related to antimicrobial
drugs, which knows no boundaries between humans
and animals. In both the EU and the USA, heated de-
bates are being waged about whether the use of fluoro-
quinolone antibiotics on food-producing animals imper-
ils the health of humans. In countries where fluoro-
quinolone have been used in the treatment of poultry,
the resistance to salmonella and campylobacter has
rapidly become more prevalent. This can exacerbate the
treatment of salmonella and campylobacter in humans.
In Finland, the situation with regard to resistance is still
good. Experts serving the National Agency for Medi-
cines have actively participated in the work of EMEA’s
(The European Agency for the Evaluation of Medicinal
Products) Veterinary Medicine Committee in preparing
guidelines for antimicrobial drugs, and have emphasised
the importance of maintaining a good resistance status.
It seems that this work is slowly bringing results.
Liisa Kaartinen
VETERINARIAN
Pharmacological Department
National Agency for Medicines
Veterinary medicine: safe and effective for the
animal being treated – and safe for people and
the environment
Editorial
Summary 
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TABU 4.2002 29
At present, various therapies can be
chosen from Table 1 below, but
there is no obligation to start any
medical treatment at all, because the
efficacy of all the treatments avail-
able is still only partial.
Immunomodulatory therapies:
interferon beta and glatiramer
Interferon beta-1b and -1a, and
glatiramer acetate since 2001, are
the first drugs capable of influencing
the course of MS and not simply
alleviating the symptoms.
Interferon beta affects the pene-
trability of the blood-brain barrier
and decreases the number of antigen
presenting cells, for example, as well
as T lymphocyte production. It is
unknown at present which of the
several effects of interferon beta is
the most essential one in the treat-
ment of MS, but a general anti-
inflammatory effect and a gamma-
interferon antagonist effect are like-
ly. Drugs with an effect on the
development of the disease are pre-
sented in Table 2. 
Introduction of treatment with
interferons for remitting, relapsing
MS is recommended as early as pos-
sible once the diagnosis is confirmed.
It appears that interferon beta thera-
py should be started as early as fol-
lowing the first demyelinating symp-
tom, especially if changes character-
istic of demyelination are detected
on MRI examination. This is possi-
bly one way of bringing about a sig-
nificant delay in the change of a
probable to a definite diagnosis of
MS. Interferon beta also has some
effect on the secondary progressive
form of MS, especially if relapses
associated with the disease continue.
A European study on interferon
beta-1b showed a statistically signif-
icant prevention of progression of
the disease and a reduction in
relapses during the study, which
lasted for two and a half years. Sub-
sequently, this preparation has also
been officially licensed to be used
for the indication of secondary pro-
gressive MS within the EU area. As
shown in Table 3, other studies have
not revealed a significant benefit of
the interferon beta therapy mea-
sured by the EDSS change, which
can be considered a conventional
method of measuring the efficacy. 
There is nevertheless no effective
Markus Färkkilä
DM, SENIOR LECTURER IN NEUROLOGY
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Summary 
Until the mid-1990s only symptomatic treatment was available for multiple sclerosis (MS).  Re-
lapses associated with MS are significantly reduced (about 30%) by drugs introduced in the 1990s
which probably to some degree also prevent the progression of the disease.
Table 1 .  Therapy alternatives.
1. Immunomodulatory therapy
2. Cytostatics
3. Intravenous immunoglobulin
4. (Plasmaphaeresis)
5. Cortisone pulse therapy 
Table 2.  Drugs affect ing the development of  MS.
Substans                 Interferon beta-1b   Interferon beta-1a   Interferon beta-1a   Glat i ramer
Name        Betaferon             Avonex                    Rebif                  Copaxone
Molecular weight    18,5 kDa              22–24 kDa                22–24 kDa           
Recommended dose 250 µg every          30 µg x 1/week im. 22 or 44 µg x 3/week  sc.  20 mg x 1/day sc.
second day  sc.     
Neutralising 38 %                    5–19 %                    22 µg:  23.8 %             -
antibodies                                                                    44 µg:  12.5 %
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treatment for the primary progres-
sive form of the disease at present.
Glatiramer acetate is a polypep-
tide compound which, similarly to
the interferons, has been found to
reduce the frequency of exacerba-
tions in remitting, relapsing multiple
sclerosis by about 30%. It can be
used as primary treatment for multi-
ple sclerosis, especially if elevation
of liver enzymes or severe depres-
sion occurs during interferon thera-
py, or if neutralising antibodies
develop and the response to inter-
feron is concurrently reduced. Glati-
ramer has no effect on the progres-
sive form of the disease either. Nor
have antibodies which would reduce
the effect of treatment with glati-
ramer been found to develop, and it
has the smallest number of adverse
reactions in comparison to the
immunomodulatory therapies avail-
able. Changes in kidney function
have been reported in association
with the therapy, and it is conse-
quently recommended that creati-
nine values be monitored at least at
the start of treatment.
The most important adverse
reaction of interferon beta is a feel-
ing similar to that of a ‘flu attack
which will pass within 4–12 hours.
At the start of interferon beta thera-
py, the condition of some patients
will temporarily become worse, but
it is usually restored to normal with-
in 1–2 months. Liver function tests
are monitored during treatment,
because elevation of hepatic en-
zymes and hepatitis occasionally
occur. If the hepatic enzymes are ele-
vated, the dose of interferon beta
should be reduced or the therapy
interrupted until the hepatic en-
zymes are restored to normal.
Increased risk of infections or malig-
nancies has not been found. Howev-
er, any globally wider experience of
interferon beta therapy only dates
back 7–8 years. Interferon beta ther-
apy should not be administered dur-
ing pregnancy, and it is recommend-
ed that the treatment be withdrawn
a month before unprotected sexual
intercourse.
The efficacy of treatment is
undergoing evaluation at present to
find out whether it is influenced by
the administration route (subcuta-
neous or intramuscular) and fre-
quency of administration chosen
(once weekly versus three times a
week or more often). The conclusion
drawn from studies published dur-
ing the last year is that increasing
the dose will increase the efficacy up
to a certain point.
In the first study of interferon
beta-1b, the efficacy of 1.8 million
IU every second day did not differ
from the placebo treatment, but the
same study showed that the efficacy
of 8 million IU every second day
was significantly more effective than
1.8 million IU doses and the placebo
treatment. On the other hand, the
interferon beta-1a therapy revealed
that 44 µg x 3/week during 2 years
was not superior in efficacy when
compared with a dose of 22 µg x
3/week measured as EDSS changes,
but after 3–4 years of the same
study the difference was also shown
clinically, and the administration of
44 µg x 3/week was slightly more
effective in comparison with the
lower dose (1). MRI monitoring
showed a difference in efficacy be-
tween the doses after as few as 2
years of monitoring and the differ-
ence was maintained during 3–4
years of monitoring to the advan-
tage of the higher dose.
Fewer neutralising antibodies to
interferon are apparently manifested
after intramuscular administration
than after subcutaneous administra-
tion. Preliminary results also suggest
a clinical significance for the neu-
tralising antibodies, since the effect
of treatment in antibody-positive
patients was reduced whereas it
remained unchanged in antibody-
negative patients. A study of inter-
feron beta-1a also showed that an
increase in the dose from 30 µg to
60 µg once a week produces no
improvement in efficacy.
Direct comparisons between
interferon beta preparations showed
Betaferon 250 µg every second day
to be more effective than Avonex 30
µg once a week (2). Similarly, pre-
liminary results of Rebif 44 µg x
3/week compared with Avonex 30
µg once a week indicate somewhat
superior results with the higher dose
(3).
Cytostatic treatment
The first alternative to interferon
beta or glatiramer treatment could
be the use of azathioprine (2.5
mg/kg, orally) to prevent relapses
and exacerbations of MS. Azathio-
prine has been shown to prevent
relapses, but there are no data con-
cerning the effect on the demyelina-
tion complexes in the brain based
on the MRI, and there are no data
about its efficacy in the prevention
of the progression of the disease (4,
5, 6). The dose of azathioprine is 50
mg x 2–3 and the treatment should
continue for a minimum period of 6
months until the clinical efficacy can
be assessed. The blood count and
hepatic enzymes should be moni-
tored during azathioprine therapy.
Reported adverse effects include
leukopaenia, lymphopaenia, allergic
reactions, pancreatitis, activation of
latent infections and possibly a
slightly increased risk of lymphoma.
Another alternative is mitox-
antrone (12 mg/m2, intravenously
Table 3.  Studies on interferon beta therapy.
-
-
-
-
+
+
+
+ +
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and every 3 months) for the preven-
tion of relapses and progression of
the disease. In the studies, mitox-
antrone was administered either
alone or in combination with
methylprednisolone. The indications
for mitoxantrone can be considered
to consist of very active remitting,
relapsing MS with no response to
interferon beta or glatiramer acetate,
and of active relapsing progressive
or secondary progressive MS. Treat-
ment with mitoxantrone has shown
significantly reduced frequency of
relapses and reduced progression of
the disease measured by the EDSS
scale. These findings are also sup-
ported by MRI examinations (7).
The use of mitoxantrone is restricted
by its cumulative cardiotoxicity
(maximum total dose 120–140 mg),
which is why its most appropriate
use is found in the treatment of
severe conditions such as halting a
severe progression and alleviating a
frequently relapsing disease. Once
the situation has calmed down pre-
ventive immunomodulatory therapy
can be reinstated.
Intravenous gammaglobulin
Yet another alternative for use in the
treatment of exacerbations of MS is
a massive intravenous dose of
immunoglobulin. Doses of 0.15–0.2
g/kg once a month, 0.4 g/kg for 5
days followed by 0.4 g/kg every sec-
ond month, and 2 g/kg once a
month, have been used in various
studies; all of these regimes have
shown an even greater reduction of
relapses than was shown with inter-
ferons or glatiramer, and a slightly
reduced progression. In comparison
with the placebo, the frequency of
lesions aggravated by gadolinium
was found to be significantly re-
duced (8, 9, 10). Since the treatment
is extremely expensive, the use is
restricted to special circumstances.
Plasmaphaeresis therapy has also
been studied in the treatment of MS.
It may be tried if an acute state of
exacerbation is not relieved by other
methods of treatment.
Treatment with steroids
An acute exacerbation or a relapse
of multiple sclerosis is treated with
methylprednisolone if the new neu-
rological symptoms caused by the
disease, or a sudden significant exac-
erbation of the old symptoms fulfil
the criteria of a relapse. Cortisone
pulsing is used for the treatment of
those states of exacerbation which
significantly reduce the ability to
function. Milder symptoms can also
be treated if they are not beginning
to show spontaneous improvement.
The treatment consists of intra-
venous administration of 1–1.5 g
methylprednisolone on 3(–5) consec-
utive mornings. Another method is
oral administration of 400 mg on
three consecutive mornings as a so-
called “home pulsing” to a patient
who has previously received several
intravenous pulses without compli-
cations. It is not medically justified
to supplement these steroid pulse
treatments by routinely tapering low
doses of cortisone. In the treatment
of optic neuritis, compared with the
placebo or small-dose treatment
with tablets, the best improvement
of sight was obtained with intra-
venous methylprednisolone. The
treatment with tablets in small doses
did not differ from the placebo.
There is no proof of the efficacy of
steroids in the long-term prognosis
of multiple sclerosis (11).
Literature
1. Freedman MS and PRISMS Study group.
PRISMS 4-year results: evidence of clinical
dose effect of interferon beta 1 a in relapsing
MS. Neurology 2000;54:2351.
2. Durelli L, Verdun E, Barbero P, Bergui M,
Versino E, Ghezzi A, Montanari E, Zaffaroni
M and the Independent Comparison of Inter-
feron (INCOMIN) Trial Study Group. Lancet
2002;359:1453-60.
3. Färkkilä M and the EVIDENCE study
group. The Evidence study: Direct compara-
tive study on IFN beta 1 a three times weekly
(Rebif) and once weekly (Avonex) in RRMS.
17th Congress of of the European Committee
for treatment and Research in Multiple Scle-
rosis (ECTRIMS), Sept.2001, Dublin, Ireland.
4. Confavreux C and Moreau T. Emerging
treatments in multiple sclerosis: azathioprine
and mofetil. Multiple Sclerosis 1996;1:379-
384.
5. Johnson KP, Brooks BR, Cohen JA and the
Copolymer 1 Multiple Sclerosis Research
Group. Copolymer 1 reduces relapse rate and
improves disability in in relapsing-remitting
multiple sclerosis: results of a phase III multi-
center, double-blind, placebo-controlled trial.
Neurology 1995;45:1268-76.
6. Yudkin PL, Ellison GW, Ghezzi A.
Overview of azathioprine treatments in multi-
ple sclerosis. Lancet 1991;338:1051-55.
7. Hartung HP, Gonsette R and the MIMS
Study Group. Mitoxantrone in progressive
multiple sclerosis: a placebo-controlled, ran-
domised, observer-blind phase III trial: clini-
cal results and three-year follow up. Neurolo-
gy 1999; 52(suppl. 2):A290. 
8. Fazekas F, Deisenhammer F, Strasser-Fuchs
S. for the Austrian Immunoglobulin in Multi-
ple Sclerosis Study Group. Randomized,
placebo-controlled trial of monthly intra-
venous immunoglobulin therapy in relapsing-
remitting multiple sclerosis. Lancet
1997;349:589-593.
9. Achiron A, Gabbay U, Gilad R et al. Intra-
venous immunoglobulin treatment in multiple
sclerosis. Effect on relapses. Neurology 1998;
50:398-402.
10. Soelberg-Sorensen PS, Wanscher B, Jensen
CV et al. Intravenous immunoglobulin G
reduces  MRI activity in relapsing multiple
sclerosis. Neurology 1998;50:1273-81.
11. Brusaferri F. and Candelise L. Steroids for
multiple sclerosis and optic neuritis: a meta-
analysis of randomised controlled trials. J
Neurol 2000; 247:435-442.
32 TABU 4.2002
Topical decongestants can be divid-
ed into sympathomimetics, cortico-
steroids, antiallergic agents (exclud-
ing corticosteroids) and other nasal
decongestants.
Sympathomimetics decongest the
nasal mucosa and decrease the mu-
cosal secretion.  Their continuous
use may nevertheless cause rebound
mucosal swelling and continuous
nasal congestion, and the maximum
period of use is 5–10 days.  The
most effective treatment for allergic
nasal congestion consists of cortico-
steroids which are used for both sea-
sonal and perennial rhinitis.  Treat-
ment for seasonal rhinitis is intro-
duced prior to exposure and contin-
ued for the entire duration of expo-
sure.  Drops of vitamin A, or of
sodium chloride in small children,
can be used for moisturising the
nasal mucosa.
A large proportion of nasal de-
congestants are over-the-counter
preparations.  All sympathomimetics
are available at the pharmacies with-
out prescription.  A nasal spray con-
taining sodium cromoglicate, one of
the group of antiallergic agents, has
been used in self-care since 1992,
and levocabastine, an antihistamine,
since 1996.  The first OTC nasal
corticosteroid spray was introduced
on to the market in 1996.
Total consumption
During the last ten years, there has
only been a slight increase in the
consumption of  topical nasal de-
congestants (ATC Code R01A).  In
1990 their consumption was over 14
defined daily doses (DDD), and in
2001 it reached over 19 DDD per
1,000 inhabitants.  About a half of
these were used in self-treatment.
Calculated on the basis of DDD,
topical nasal decongestants are used
more frequently in self-treatment
than are cough or cold preparations.
In 2001 they were bought at retail
prices to a value of over EUR 5 mil-
lion.
Among topical nasal deconges-
tants, the consumption of cortico-
steroids has increased the most (Fig.
1).  The growth was slow until the
mid-1990s, increasing thereafter.
The increased consumption was in-
fluenced by beclomethasone becom-
ing an OTC preparation in 1996.
The consumption of sympathomim-
etics had been falling, but it has
turned into a slight rise during re-
cent years.  A consumption peak
was to be seen in 1993, when sever-
al sympathomimetics were available
on the market.  The  consumption
of antiallergic agents increased
slightly after 1992 when the nasal
spray of sodium cromoglicate be-
came an OTC preparation.  The
consumption has remained stable
ever since, and the release of levo-
cabastine on to the OTC market in
1996 has had no effect on total con-
sumption of this group of drugs.
Seasonal fluctuation in 
consumption
The consumption graph of cortico-
steroids reveals a significant increase
in consumption of the more recent
introductions on to the market and
of other corticosteroids (other corti-
costeroids = mometasone and triam-
cinolone) (Fig. 2). The consumption
of older drugs, budesonide and be-
clomethasone, has decreased. The
consumption of  fluticasone has in
recent years amounted to about a
third of the total consumption of
corticosteroids.
The consumption of cortico-
steroid preparations is significantly
increased during the spring-time al-
lergies (Fig. 3).  The sale of both
prescription and OTC preparations
is increased during March-April and
correspondingly decreased during
July-August when the exposure to
allergens is reduced. The consump-
tion of other antiallergic agents is
steady with only a small peak seen
in the spring.
The winter-time ‘flu period leads
to a peak in the consumption of
sympathomimetics in February, and
the consumption is reduced in the
summer and increased again in the
autumn when the new ‘flu period
starts.  The increase in consumption
is brought about especially by the
increased sale of xylometazoline
preparations.
The monthly consumption
graphs also show an increased con-
sumption of nasal moisturising
preparations in the autumn and win-
ter. 
Based on the monthly consump-
tion graphs in 2001, it can be
claimed that the use of topical nasal
decongestants appears on the whole
to be reasonable. Sympathomimetics
are used mostly during ‘flu periods,
the use of corticosteroids is concen-
trated on the periods of allergy, and
other preparations – including nasal
moisturising preparations – are also
used as alternatives.
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Figure 1 .  Consumption of  nasal
decongestants (ATC Code R01A).  
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corticosteroids.
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